Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New agents for hypercholesterolemia designed in Japan

July 2, 2012

Somatuline approved in Japan

July 2, 2012

Mitsubishi Tanabe drug approved for type 2 diabetes

June 29, 2012

Sanwa and Fuji submit application for hyperuricemia and gout treatment in Japan

June 29, 2012

FDA accepts Shionogi NDA for review

June 29, 2012

New notum-directed antibodies may be useful to treat osteoporosis

June 29, 2012

Studies yield encouraging VRS-317 pharmacodynamic and safety data

June 29, 2012

Janssen-Cilag applies for European approval of canagliflozin

June 28, 2012

FDA approves first new weight loss drug in 13 years

June 28, 2012

New fusion proteins for bone disorders designed in Korea

June 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....